References
- Bhatta RS, Kumar D, Chhonker YS, et al. (2010a). Bioanalytical method development and validation of novel antithrombotic agent S002-333 by LC-MS/MS and its application to pharmacokinetic studies. Biomed Chromatogr 24:1234–9
- Bhatta RS, Kumar D, Chhonker YS, et al. (2010b). Bioanalytical method development and validation for simultaneous estimation of (R)- and (S)-isomers of S002-333: a potent novel anti-thrombotic agent using LC–MS/MS. Med Chem Res 20:1581–8
- Chackalamannil S, Wang Y, Greenlee WJ, et al. (2008). Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51:3061–4
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- el-Saharty YS. (2003). Simultaneous high-performance liquid chromatographic assay of furosemide and propranolol HCL and its application in a pharmacokinetic study. J Pharm Biomed Anal 33:699–709
- Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. (2004). The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2:561–73
- Gaur S, Fatima Z, Dixit A, et al. (2007). 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents. Patent WO/2006/070385
- Jackson SP, Nesbitt WS, Kulkarni S. (2003). Signaling events underlying thrombus formation. J Thromb Haemost 1:1602–12
- Kahn ML. (2004). Platelet-collagen responses: molecular basis and therapeutic promise. Semin Thromb Hemost 30:419–25
- Kogushi M, Matsuoka T, Kawata T, et al. (2011). The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 657:131–7
- Oh E, Ban E, Woo JS, Kim CK. (2006). Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography. Anal Bioanal Chem 386:1931–6
- Saelman EU, Horton LF, Barnes MJ, et al. (1993). Platelet adhesion to cyanogen-bromide fragments of collagen alpha 1(I) under flow conditions. Blood 82:3029–33
- Sarratt KL, Chen H, Zutter MM, et al. (2005). GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 106:1268–77
- Sashidhara KV, Kumar A, Kumar M, et al. (2011). Synthesis of novel 3-carboxamide-benzocoumarin derivatives as orally active antithrombotic agents. Bioorg Med Chem Lett 21:7034–40
- Saxena A, Jain GK, Siddiqui HH, et al. (2013). In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies 44:295–308
- Surin WR, Barthwal MK, Dikshit M. (2008). Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res 122:786–803
- Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H. (2003). Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol Disord 3:125–40
- White RH. (2003). The epidemiology of venous thromboembolism. Circulation 107:I4–8
- Zhang H, Lowenberg EC, Crosby JR, et al. (2010). Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116:4684–92